Tags

Type your tag names separated by a space and hit enter

[Cost-effectiveness of lowering of blood cholesterol using simvastatin and cholestyramine].
Ned Tijdschr Geneeskd. 1991 Apr 13; 135(15):655-9.NT

Abstract

With use of a model of the costs and effects of cholesterol lowering therapy in the primary prevention of coronary heart disease, the cost-effectiveness of simvastatin and cholestyramine in the Netherlands have been estimated. Costs per year of life saved by cholestyramine therapy are several times greater than those of simvastatin therapy and compared unfavorably with those of generally accepted health care programs in the Netherlands. Cholesterol-lowering with simvastatin in men can be cost-effective when therapy is initiated at an early age. At cholesterol levels between 6.5 and 8 mmol/l, however, therapy should be restricted to men with at least one, preferably two additional risk factors such as hypertension or diabetes mellitus. Among women, cholesterol lowering can only be cost-effective when therapy is limited to women with diabetes mellitus or severely elevated serum cholesterol levels.

Authors+Show Affiliations

Martens LL
Erasmus Universiteit, Instituut voor Medische Technology Assessment, Rotterdam.
Rutten FF
No affiliation info available
Kuijpens JL
No affiliation info available
Winter J
No affiliation info available

MeSH

AdultAge FactorsAnticholesteremic AgentsCholestyramine ResinCost-Benefit AnalysisFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaLovastatinMaleMiddle AgedNetherlandsSex FactorsSimvastatin

Pub Type(s)

English Abstract
Journal Article
Research Support, Non-U.S. Gov't

Language

dut

PubMed ID

1903849

Citation

Martens, L L., et al. "[Cost-effectiveness of Lowering of Blood Cholesterol Using Simvastatin and Cholestyramine]." Nederlands Tijdschrift Voor Geneeskunde, vol. 135, no. 15, 1991, pp. 655-9.
Martens LL, Rutten FF, Kuijpens JL, et al. [Cost-effectiveness of lowering of blood cholesterol using simvastatin and cholestyramine]. Ned Tijdschr Geneeskd. 1991;135(15):655-9.
Martens, L. L., Rutten, F. F., Kuijpens, J. L., & Winter, J. (1991). [Cost-effectiveness of lowering of blood cholesterol using simvastatin and cholestyramine]. Nederlands Tijdschrift Voor Geneeskunde, 135(15), 655-9.
Martens LL, et al. [Cost-effectiveness of Lowering of Blood Cholesterol Using Simvastatin and Cholestyramine]. Ned Tijdschr Geneeskd. 1991 Apr 13;135(15):655-9. PubMed PMID: 1903849.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Cost-effectiveness of lowering of blood cholesterol using simvastatin and cholestyramine]. AU - Martens,L L, AU - Rutten,F F, AU - Kuijpens,J L, AU - Winter,J, PY - 1991/4/13/pubmed PY - 1991/4/13/medline PY - 1991/4/13/entrez SP - 655 EP - 9 JF - Nederlands tijdschrift voor geneeskunde JO - Ned Tijdschr Geneeskd VL - 135 IS - 15 N2 - With use of a model of the costs and effects of cholesterol lowering therapy in the primary prevention of coronary heart disease, the cost-effectiveness of simvastatin and cholestyramine in the Netherlands have been estimated. Costs per year of life saved by cholestyramine therapy are several times greater than those of simvastatin therapy and compared unfavorably with those of generally accepted health care programs in the Netherlands. Cholesterol-lowering with simvastatin in men can be cost-effective when therapy is initiated at an early age. At cholesterol levels between 6.5 and 8 mmol/l, however, therapy should be restricted to men with at least one, preferably two additional risk factors such as hypertension or diabetes mellitus. Among women, cholesterol lowering can only be cost-effective when therapy is limited to women with diabetes mellitus or severely elevated serum cholesterol levels. SN - 0028-2162 UR - https://www.unboundmedicine.com/medline/citation/1903849/[Cost_effectiveness_of_lowering_of_blood_cholesterol_using_simvastatin_and_cholestyramine]_ DB - PRIME DP - Unbound Medicine ER -